Investigating proteins involved in cancer cell growth and survival.
Core B: Proteomics Core.
This study is looking at how certain proteins affect the growth of deadly cancers like breast cancer and melanoma, to find new ways to treat these conditions, especially with a drug called palbociclib.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11046680 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular mechanisms behind certain deadly cancers, including breast cancer and melanoma, by studying proteins that regulate cell growth and division. The team will identify specific proteins and their modifications that play a role in the cancer pathway driven by cyclin D and Cdk4/6. By using advanced techniques like phosphoproteomics, they aim to uncover how these proteins interact and respond to treatments like the Cdk4 inhibitor palbociclib. This research could lead to new insights into cancer biology and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer, melanoma, or other cancers associated with mutations in the cyclin D/Cdk4 pathway.
Not a fit: Patients with cancers not related to the cyclin D/Cdk4 pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with aggressive cancers by identifying new therapeutic targets.
How similar studies have performed: Previous research has shown success in targeting the cyclin D/Cdk4 pathway, particularly with the use of palbociclib in treating certain cancers.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Jackson, Peter Kent — Stanford University
- Study coordinator: Jackson, Peter Kent
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.